Breaking News Instant updates and real-time market news.

ATRA

Atara Biotherapeutics

$18.90

0.45 (2.44%)

, MRK

Merck

$62.55

-0.09 (-0.14%)

08:07
04/21/17
04/21
08:07
04/21/17
08:07

Atara Biotherapeutics announces collaboration with Merck

Atara Biotherapeutics (ATRA) announced that it has entered into a clinical trial collaboration agreement with Merck (MRK), to evaluate Atara Bio's allogeneic Epstein-Barr virus, or EBV,-specific cytotoxic T lymphocytes, or ATA129, in combination with Merck's anti-PD-1 therapy, KEYTRUDA, in patients with platinum resistant or recurrent EBV-associated NPC. The Phase 1/2 trial will evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination and is planned for initiation in 2018.

ATRA

Atara Biotherapeutics

$18.90

0.45 (2.44%)

MRK

Merck

$62.55

-0.09 (-0.14%)

  • 22

    Apr

  • 02

    May

  • 03

    May

  • 07

    May

  • 10

    May

  • 27

    May

  • 06

    Jun

  • 09

    Jun

  • 14

    Jun

ATRA Atara Biotherapeutics
$18.90

0.45 (2.44%)

03/15/17
SBSH
03/15/17
NO CHANGE
Target $10
SBSH
Sell
Citi sees 50% downside risk in shares of Atara
Citi analyst Yigal Nochomovitz reiterates a Sell rating and $10 price target on shares of Atara Biotherapeutics following the stock's 40% rally this morning. The price target reflects 50% downside from current levels, the analyst points out. The stock rally came in the absence of new clinical data and with minimal updates on the pipeline, Nochomovitz tells investors in a research note. He continues to believe Atara's markets are relatively niche.
12/14/16
SBSH
12/14/16
NO CHANGE
Target $8
SBSH
Sell
Citi says Atara Biotherapeutics sell thesis is working
Citi analyst Yigal Nochomovitz believes his thesis on Atara Biotherapeutics is working after the company this week said it will not be able to start Phase 3 trials by the end of 2016. The analyst keeps a Sell rating on the shares with an $8 price target.
11/21/16
WBLR
11/21/16
NO CHANGE
WBLR
Outperform
William Blair views Atara as 'overlooked and misunderstood'
William Blair analyst John Sonnier feels Atara Biotherapeutics, following last year's failure of a molecularly targeted pipeline candidate in a Phase II protein-energy wasting trial, has been "overlooked and misunderstood" by investors. Since the failure, the company has made "important advances with a differentiated T-cell platform," with plans to initiate two Phase III clinical trials by the end of this year, Sonnier tells investors in a research note. He believes Atara shares are fundamentally undervalued and reiterates an Outperform rating on the shares.
10/24/16
JEFF
10/24/16
INITIATION
Target $23
JEFF
Buy
Atara Biotherapeutics assumed with a Buy at Jefferies
Jefferies analyst Gena Wang assumed coverage of Atara Biotherapeutics with a Buy rating and $23 price target. The company's off-the-shelf cytotoxic T-lymphocytes technology could offer differentiated advantages, Wang contends.
MRK Merck
$62.55

-0.09 (-0.14%)

04/20/17
JEFF
04/20/17
NO CHANGE
Target $51
JEFF
Underperform
Jefferies lowers Merck estimates, drops target to $51
Jefferies analyst Jeffrey Holford lowered his earnings estimates for Merck by up to 3% citing concerns on pricing for Januvia/Janumet. The analyst notes that his mid-term estimates are now up to 11% below consensus. Holford expects Keytruda, Januvia and Gardasil to miss expectations Q1. He cut his price target for Merck to $51 from $52 and keeps an Underperform rating on the name.
04/04/17
STFL
04/04/17
NO CHANGE
STFL
NewLink Genetics should be bought on weakness after data, says Stifel
Stifel analyst Stephen Willey said NewLink Genetics' (NLNK) combination of indoximod and Merck's (MRK) pembrolizumab in patients with treatment-naive melanoma demonstrated an overall response rate, or ORR, that is "essentially identical" to the previously-reported results from the Incyte (INCY)-Merck study of epacadostat/pembrolizumab. The lower rate of complete responses he doesn't "find terribly surprising" given what is already known about the current indoximod formulation, he tells investors. Willey, who views today's weakness as an interesting buying opportunity ahead of P1/2 data on the atezolizumab + GDC-0919 combination, keeps a Buy rating on Newlink shares.
04/04/17
RBCM
04/04/17
NO CHANGE
RBCM
Incyte price target raised to $157 from $138 at RBC Capital
RBC Capital analyst Simos Simeonidis raised his price target on Incyte (INCY) after Incyte and Bristol-Myers (BMY) announced that they would conduct Phase III trials of the combination of Incyte's epacadostat and Bristol-Myers' Opdivo in 1L lung and head-and-neck cancer. The analyst notes that Merck last week made a similar announcement regarding the use of epacadostat and Merck's Keutruda in additional Phase III trials. Simeonidis keeps an Outperform rating on Incyte.
04/03/17
JPMS
04/03/17
NO CHANGE
JPMS
Overweight
Incyte trial news 'another clear positive,' says JPMorgan
JPMorgan analyst Cory Kasimov views the announcement of epacadostat and nivolumab combo moving into Phase 3 studies in first-line non-small cell lung cancer as well as first-line head and neck cancer in 2017 as "another clear positive" for Incyte (INCY). The stock in early trading is up 5% to $140.73. The news expands the breadth of the epacadostat combinations beyond just Merck (MRK) and could ease fears that Bristol-Myers (BMY) is only focused on its internal molecule, Kasimov tells investors in a research note. The analyst continues to be encouraged by Incyte's progress in immuno-oncology and keeps an Overweight rating on the shares.

TODAY'S FREE FLY STORIES

16:39
06/23/17
06/23
16:39
06/23/17
16:39
General news
Moody's raises Greece rating to Caa2 from Caa3, outlook to positive from stable »

Moody's has upgraded…

CFCO

CF Corporation

$11.42

-0.04 (-0.35%)

16:38
06/23/17
06/23
16:38
06/23/17
16:38
Hot Stocks
Breaking Hot Stocks news story on CF Corporation »

Mason Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKS

AK Steel

$6.65

0.35 (5.56%)

, X

U.S. Steel

$22.25

1.18 (5.60%)

16:34
06/23/17
06/23
16:34
06/23/17
16:34
General news
On The Fly: Top stock stories for Friday »

Stocks opened in quiet…

AKS

AK Steel

$6.65

0.35 (5.56%)

X

U.S. Steel

$22.25

1.18 (5.60%)

PTLA

Portola Pharmaceuticals

$56.13

17.88 (46.75%)

BAC

Bank of America

$22.82

-0.11 (-0.48%)

C

Citi

$63.41

-0.21 (-0.33%)

GS

Goldman Sachs

$217.19

-2.58 (-1.17%)

JPM

JPMorgan

$86.86

-0.16 (-0.18%)

MS

Morgan Stanley

$43.69

-0.92 (-2.06%)

WFC

Wells Fargo

$52.45

-0.04 (-0.08%)

SNCR

Synchronoss

$16.24

4.06 (33.33%)

BBBY

Bed Bath & Beyond

$29.65

-4.09 (-12.12%)

BBRY

BlackBerry

$9.71

-1.35 (-12.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 23

    Jun

  • 23

    Jun

  • 24

    Jun

  • 26

    Jun

  • 29

    Jun

  • 14

    Jul

  • 14

    Jul

  • 18

    Jul

  • 25

    Jul

  • 25

    Jul

  • 12

    Oct

  • 12

    Oct

  • 17

    Oct

  • 15

    Jan

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

FMC

FMC Corporation

$74.78

0.52 (0.70%)

16:31
06/23/17
06/23
16:31
06/23/17
16:31
Hot Stocks
FMC Corporation to sell Omega-3 business to Pelagia AS, terms not disclosed »

FMC Corporation has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
06/23/17
06/23
16:30
06/23/17
16:30
Options
Preliminary option volume of 15.0M today »

Preliminary option volume…

ESNC

EnSync

$0.33

0.0151 (4.79%)

16:25
06/23/17
06/23
16:25
06/23/17
16:25
Syndicate
Breaking Syndicate news story on EnSync »

EnSync files $25M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

PTLA

Portola Pharmaceuticals

$56.13

17.88 (46.75%)

16:25
06/23/17
06/23
16:25
06/23/17
16:25
Conference/Events
Portola Pharmaceuticals hold a conference call »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 23

    Jun

  • 24

    Jun

DTE

DTE Energy

$108.89

-0.69 (-0.63%)

16:24
06/23/17
06/23
16:24
06/23/17
16:24
Earnings
DTE Energy backs FY17 operating EPS view $5.15-$5.46, consensus $5.33 »

DTE Energy will meet with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jul

$NSD

NASDAQ Market Internals

16:17
06/23/17
06/23
16:17
06/23/17
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VHI

Valhi Inc

$3.29

0.14 (4.44%)

16:16
06/23/17
06/23
16:16
06/23/17
16:16
Hot Stocks
Valhi Inc termiantes purchase deal for sale of Waste Control Specialists »

As previously announced,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

16:16
06/23/17
06/23
16:16
06/23/17
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GBL

GAMCO Investors

$29.63

-0.24 (-0.80%)

, LSXMA

Liberty SiriusXM

$40.83

0.79 (1.97%)

16:14
06/23/17
06/23
16:14
06/23/17
16:14
Hot Stocks
Breaking Hot Stocks news story on GAMCO Investors, Liberty SiriusXM »

Gabelli reports 5.22%…

GBL

GAMCO Investors

$29.63

-0.24 (-0.80%)

LSXMA

Liberty SiriusXM

$40.83

0.79 (1.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WETF

WisdomTree

$9.98

-0.11 (-1.09%)

16:13
06/23/17
06/23
16:13
06/23/17
16:13
Hot Stocks
WisdomTree to close, liquidate three ETFs »

WisdomTree announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CONN

Conn's

$17.10

0.15 (0.88%)

16:11
06/23/17
06/23
16:11
06/23/17
16:11
Hot Stocks
Breaking Hot Stocks news story on Conn's »

Point72 Asset reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Wal-Mart

$74.87

-0.655 (-0.87%)

, WFM

Whole Foods

$42.95

-0.255 (-0.59%)

16:11
06/23/17
06/23
16:11
06/23/17
16:11
Periodicals
Wal-Mart not weighing offer for Whole Foods, Reuters reports »

Wal-Mart (WMT) is not…

WMT

Wal-Mart

$74.87

-0.655 (-0.87%)

WFM

Whole Foods

$42.95

-0.255 (-0.59%)

AMZN

Amazon.com

$1,003.74

2.44 (0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

APDN

Applied DNA Sciences

$1.09

0.06 (5.83%)

16:10
06/23/17
06/23
16:10
06/23/17
16:10
Hot Stocks
Applied DNA Sciences receives order to tag 27.5M pounds of cotton »

Applied DNA Sciences is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOCO

Mocon

16:08
06/23/17
06/23
16:08
06/23/17
16:08
Hot Stocks
Gabelli liquidates stake in Mocon »

As a result of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TKTDY

Takata

$3.15

1.2199 (63.21%)

16:03
06/23/17
06/23
16:03
06/23/17
16:03
Periodicals
Takata to seek bankruptcy protection as soon as Sunday, WSJ reports »

Takata intends to seek…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TIPT

Tiptree Financial

16:02
06/23/17
06/23
16:02
06/23/17
16:02
Hot Stocks
Tiptree Financial repurchases 1M shares from Nomura Securities »

Tiptree has repurchased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFBC

Preferred Bank

16:01
06/23/17
06/23
16:01
06/23/17
16:01
Hot Stocks
Preferred Bank raises quarterly dividend 11% to 20c per share »

Preferred Bank reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

16:01
06/23/17
06/23
16:01
06/23/17
16:01
Hot Stocks
Amgen receives positive CHMP opinion to expand use of Mimpara »

Amgen announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jul

  • 19

    Jul

  • 14

    Aug

  • 03

    Feb

WFM

Whole Foods

$43.20

-0.06 (-0.14%)

, WMT

Wal-Mart

$74.66

-0.86 (-1.14%)

15:56
06/23/17
06/23
15:56
06/23/17
15:56
Periodicals
Wal-Mart not considering bid for Whole Foods, Reuters says 

Reuters cites a source.

WFM

Whole Foods

$43.20

-0.06 (-0.14%)

WMT

Wal-Mart

$74.66

-0.86 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBR

Petrobras

$7.77

-0.03 (-0.38%)

, FTI

TechnipFMC

$26.69

-0.045 (-0.17%)

15:30
06/23/17
06/23
15:30
06/23/17
15:30
Periodicals
Petrobras seeks to change riser contract with TechnipFMC, Reuters reports »

Petrobras (PBR) is in…

PBR

Petrobras

$7.77

-0.03 (-0.38%)

FTI

TechnipFMC

$26.69

-0.045 (-0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

EZPW

EZCORP

$9.00

0.25 (2.86%)

15:22
06/23/17
06/23
15:22
06/23/17
15:22
Hot Stocks
Breaking Hot Stocks news story on EZCORP »

Rovida Advisors reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IWM

iShares Trust Russell 2000 Index Fund

$140.55

0.57 (0.41%)

, RUT

Russell 2000 Index

15:22
06/23/17
06/23
15:22
06/23/17
15:22
Technical Analysis
On The Fly: Weekly technical notes for Russell 2000 »

The Russell 2000 (RUT) is…

IWM

iShares Trust Russell 2000 Index Fund

$140.55

0.57 (0.41%)

RUT

Russell 2000 Index

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.